CD5L Antikörper

Produktnummer ABIN7490726

Produktdetails anti-CD5L Antikörper

Target: CD5L (CD5 Molecule-Like (CD5L))

Fragment: Fc fragment

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser CD5L Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Produktmerkmale: Rabbit/Human Fc chimeric IgG1

Aufreinigung: Purified from cell culture supernatant by affinity chromatography

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow Cyt  1:100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Haltbarkeit: 12 months

Details zu CD5L

Target: CD5L (CD5 Molecule-Like (CD5L))

Andere Bezeichnung: CD5L (CD5L Produkte)

Synonyme: AIM antikoerper, API6 antikoerper, PRO229 antikoerper, SP-ALPHA antikoerper, Spalpha antikoerper, 1/6 antikoerper, AAC-11 antikoerper, AI047839 antikoerper, Api6 antikoerper, CT2 antikoerper, Pdp antikoerper, Sp-alpha antikoerper, CD5L antikoerper, CD5 molecule like antikoerper, CD5 antigen-like antikoerper, Cd5 molecule-like antikoerper, CD5 molecule-like antikoerper, scavenger receptor cysteine-rich domain superfamily protein-like antikoerper, CD5L antikoerper, Cd5l antikoerper, LOC100375137 antikoerper

Hintergrund: AIM, API6, CT-2, hAIM, PRO229, SP-ALPHA, Spalpha,
Description: Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflamed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis, associates with cytosolic FASN, inhibiting fatty acid synthase activity and leading to lipolysis, the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC, the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells, where it decreases the content of polyunsaturated fatty acyls (PUFA), affecting two metabolic proteins MSMO1 and CYP51A1, which synthesize ligands of RORC, limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity-associated autoimmunity via its association with IgM, interfering with the binding of IgM to Fcalpha/mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed:24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed:16030018, PubMed:24223991, PubMed:24583716, PubMed:25713983).

UniProt: O43866